Bladder and upper-tract urothelial cancer

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Urothelial carcinoma arises throughout the renal pelvis, ureter, bladder and urethra; bladder disease is divided into non-muscle-invasive and muscle-invasive states, while upper-tract anatomy changes biopsy and surgical choices. Smoking is the leading modifiable risk because urinary carcinogens contact the entire urothelium and continue to influence recurrence and second-field tumours. Aromatic amines in historical dye, rubber, leather and industrial exposure increase risk after a long latency and may have compensation implications. FGFR3 and related alterations often drive recurrent low-grade papillary tumours that remain superficial but require long surveillance. TP53 and RB disruption characterises carcinoma in situ and high-grade disease with greater risk of lamina propria and muscle invasion.

Recognition depends on the tempo, host context and anatomical pattern rather than one isolated result. Intermittent painless red urine is the classic presentation; a single episode deserves investigation despite anticoagulation or a presumed infection. Frequency, urgency and dysuria with negative cultures can indicate carcinoma in situ, although infection and benign causes remain common. Painful inability to void with heavy haematuria requires urgent catheter, irrigation and endoscopic haemostasis assessment. Investigation should answer immediate safety, diagnostic confirmation and extent in that order. Flexible cystoscopy A normal cystoscopy does not evaluate the upper tracts; flat carcinoma in situ may be subtle and needs cytology or directed biopsy when suspected. CT urography Use an appropriate contrast and excretory protocol; ultrasound may be chosen first in selected low-risk or contrast-limited settings but is less sensitive for urothelial lesions. Transurethral resection of bladder tumour The specimen must include detrusor muscle for accurate staging except selected clearly low-risk lesions; document size, number, site, completeness and perforation.

Management is determined by physiological urgency, disease extent, treatment intent and the person's priorities. The pathway moves through examine bladder and upper tracts, then risk-stratify after high-quality turbt, then choose radical or bladder-preserving treatment; each transition requires named multidisciplinary ownership. Follow-up must anticipate clot retention and haemorrhage, hydronephrosis and renal failure, recurrence and progression while measuring function and treatment toxicity.

Key points

Visible haematuria is a pivotal clue in Bladder and upper-tract urothelial cancer: Intermittent painless red urine is the classic presentation; a single episode deserves investigation despite anticoagulation or a presumed infection.
Immediate priority in unstable Bladder and upper-tract urothelial cancer: Resuscitate, check haemoglobin and coagulation, obtain large-bore three-way catheter irrigation for clot retention with urgent urology, and decompress an infected obstructed upper tract by stent or nephrostomy alongside antibiotics.
Flexible cystoscopy is used early to inspect the bladder directly in haematuria assessment and identify lesions for resection. A normal cystoscopy does not evaluate the upper tracts; flat carcinoma in situ may be subtle and needs cytology or directed biopsy when suspected.
CT urography refines the next decision because use an appropriate contrast and excretory protocol; ultrasound may be chosen first in selected low-risk or contrast-limited settings but is less sensitive for urothelial lesions.
Examine bladder and upper tracts: Confirm urinalysis, culture when infection is plausible, renal function and blood count, but do not dismiss visible haematuria because anticoagulation is present.
Risk-stratify after high-quality TURBT: Use immediate intravesical mitomycin for eligible low- or intermediate-risk disease when perforation and significant bleeding are absent.
A major avoidable harm is clot retention and haemorrhage; Heavy bleeding causes painful obstruction, anaemia and transfusion or endoscopic haemostasis need.
A common diagnostic trap is urinary infection: Dysuria and haematuria can arise from infection, but visible blood that persists or recurs after treatment still needs cancer assessment.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Tobacco exposure

Smoking is the leading modifiable risk because urinary carcinogens contact the entire urothelium and continue to influence recurrence and second-field tumours.

Occupational carcinogens

Aromatic amines in historical dye, rubber, leather and industrial exposure increase risk after a long latency and may have compensation implications.

Chronic urothelial injury

Pelvic radiotherapy, cyclophosphamide, chronic inflammation and selected infections contribute to bladder cancer through DNA damage or metaplasia.

Inherited susceptibility

Lynch syndrome particularly increases upper-tract urothelial carcinoma, making age, family history and mismatch-repair assessment clinically relevant.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Papillary pathway
FGFR3 and related alterations often drive recurrent low-grade papillary tumours that remain superficial but require long surveillance.
2
Flat high-grade pathway
TP53 and RB disruption characterises carcinoma in situ and high-grade disease with greater risk of lamina propria and muscle invasion.
3
Field cancerisation
Carcinogen exposure affects the whole urothelium, allowing synchronous and metachronous tumours in bladder, ureter, renal pelvis and urethra.
4
Muscle and lymphatic invasion
Once tumour reaches detrusor, nodal and distant metastatic risk rises sharply and bladder-only endoscopic treatment is inadequate.
5
Upper-tract obstruction
Ureteric or renal-pelvis tumour narrows urine flow, causing hydronephrosis, infection and renal loss that may limit cisplatin fitness.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Visible haematuria

Intermittent painless red urine is the classic presentation; a single episode deserves investigation despite anticoagulation or a presumed infection.

Irritative voiding symptoms

Frequency, urgency and dysuria with negative cultures can indicate carcinoma in situ, although infection and benign causes remain common.

Clot retentionRed flag

Painful inability to void with heavy haematuria requires urgent catheter, irrigation and endoscopic haemostasis assessment.

Upper-tract pattern

Flank pain, haematuria, hydronephrosis or declining unilateral renal function can indicate ureteric or renal-pelvis tumour.

Invasive pelvic disease

Hydronephrosis, pelvic pain, leg oedema, weight loss or fistula suggests local extension or nodal burden.

Metastatic symptoms

Bone pain, cough, constitutional decline or abnormal liver tests may reflect distant urothelial spread.

Red flags requiring action

Painless visible haematuria requires urgent urinary-tract cancer assessment even if it settles or anticoagulation is present.
Clots, suprapubic pain and inability to void suggest clot retention.
Flank pain, fever and hydronephrosis suggests infected upper-tract obstruction.
Persistent irritative urinary symptoms with sterile cultures may reflect carcinoma in situ.
Hydronephrosis, pelvic pain, weight loss or renal impairment suggests invasive or upper-tract disease.
A high-grade T1 tumour lacks detrusor muscle in the first TURBT specimen and may be understaged.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Flexible cystoscopyFirst step
Why
Inspect the bladder directly in haematuria assessment and identify lesions for resection.
Interpretation and limitations
A normal cystoscopy does not evaluate the upper tracts; flat carcinoma in situ may be subtle and needs cytology or directed biopsy when suspected.
02
CT urography
Why
Assess kidneys, collecting systems and ureters for upper-tract tumour, obstruction and other haematuria causes.
Interpretation and limitations
Use an appropriate contrast and excretory protocol; ultrasound may be chosen first in selected low-risk or contrast-limited settings but is less sensitive for urothelial lesions.
03
Transurethral resection of bladder tumour
Why
Completely map and resect visible bladder tumour where feasible and obtain diagnostic stage and grade.
Interpretation and limitations
The specimen must include detrusor muscle for accurate staging except selected clearly low-risk lesions; document size, number, site, completeness and perforation.
04
Repeat TURBT
Why
Detect residual or understaged high-risk non-muscle-invasive cancer.
Interpretation and limitations
Repeat within the pathway interval for high-grade T1, incomplete initial resection or absent muscle where its absence compromises staging.
05
Urine cytology
Why
Detect high-grade urothelial carcinoma and carcinoma in situ when cystoscopy or symptoms raise suspicion.
Interpretation and limitations
High-grade cytology with no visible bladder lesion prompts upper-tract, prostatic urethral and enhanced cystoscopic assessment; negative cytology poorly excludes low-grade disease.
06
Muscle-invasive staging
Why
Define pelvic extent, nodes and distant metastasis before radical treatment.
Interpretation and limitations
Use contrast CT chest, abdomen and pelvis or protocolled alternatives, evaluating renal function and hydronephrosis for cisplatin and bladder-preservation fitness.
07
Ureteroscopy and upper-tract biopsy
Why
Confirm grade and map an upper-tract lesion when kidney-sparing or diagnostic decisions require tissue.
Interpretation and limitations
Small samples can undergrade; combine ureteroscopic appearance, cytology and CT invasion features before choosing conservative treatment.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Urinary infection

Dysuria and haematuria can arise from infection, but visible blood that persists or recurs after treatment still needs cancer assessment.

Stone disease

Colic and microscopic or visible haematuria may reflect calculus; imaging identifies stone while excluding an obstructing tumour.

Renal-cell carcinoma

A solid renal cortical mass causes haematuria but arises outside the urothelial collecting system and follows a different surgical pathway.

Prostate bleeding

Benign enlargement and prostate cancer can bleed, but should not be assumed without cystoscopic and upper-tract evaluation when indicated.

Radiation cystitis

Late telangiectasia after pelvic radiotherapy causes haematuria and can coexist with a radiation-associated secondary urothelial cancer.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01HaematuriaExamine bladder and upper tractsFirst stepVisible haematuria or qualifying persistent non-visible haematuria prompts suspected urothelial cancer assessment.

1Confirm urinalysis, culture when infection is plausible, renal function and blood count, but do not dismiss visible haematuria because anticoagulation is present.
2Perform flexible cystoscopy and appropriate upper-tract imaging, usually CT urography, through the urgent pathway.
3Resect or biopsy identified lesions and complete an independent renal or prostate work-up when anatomy indicates another primary.

02NMIBCRisk-stratify after high-quality TURBTPathology shows Ta, T1 or carcinoma in situ without detrusor muscle invasion.

1Integrate grade, stage, CIS, size, multiplicity, recurrence and muscle sampling; repeat TURBT for high-grade T1, incomplete resection or compromised staging.
2Use immediate intravesical mitomycin for eligible low- or intermediate-risk disease when perforation and significant bleeding are absent.
3Offer BCG induction and maintenance or discuss early radical cystectomy for high- and very-high-risk disease according to recurrence and progression risk.

03MIBCChoose radical or bladder-preserving treatmentTURBT demonstrates detrusor muscle invasion without unresectable or distant disease.

1Stage chest, abdomen and pelvis, assess hydronephrosis, renal and hearing function, performance and complete TURBT, then discuss in the bladder MDT.
2Offer cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy and pelvic lymphadenectomy to eligible patients.
3For suitable patients choosing preservation, use maximal TURBT followed by radiosensitised chemoradiotherapy with cystoscopic response assessment and salvage-cystectomy access.

04Upper tractPreserve kidney selectivelyImaging and ureteroscopy identify renal-pelvis or ureteric urothelial carcinoma.

1Classify low versus high risk using grade, size, multifocality, cytology, imaging invasion and hydronephrosis, recognising biopsy undergrading.
2Offer kidney-sparing endoscopic or segmental treatment with stringent ureteroscopic surveillance for suitable low-risk disease.
3Use radical nephroureterectomy with bladder cuff for high-risk disease and plan perioperative systemic and intravesical treatment according to pathology and renal function.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Reduces implantation and early recurrence after complete TURBT in selected low- and intermediate-risk disease.

Intravesical mitomycin

For eligible non-muscle-invasive bladder cancer, use a single intravesical instillation commonly containing 40 mg mitomycin in the protocol-defined diluent within 24 hours of TURBT, retained for the locally specified period.

Do not give when bladder perforation, extensive resection, significant bleeding or unsafe catheterisation is suspected; use cytotoxic handling and counsel about chemical cystitis and skin contact.

Creates local immune control for carcinoma in situ and high-risk non-muscle-invasive urothelial cancer.

Intravesical BCG

Use the selected licensed BCG product once weekly for 6 induction instillations, followed by risk-adapted maintenance for up to 1–3 years according to high-risk NMIBC protocol.

Delay with visible haematuria, traumatic catheterisation, symptomatic infection or early after TURBT; systemic fever or sepsis after BCG requires urgent specialist assessment and antituberculous treatment when suspected.

Provides cisplatin-based perioperative or systemic therapy for eligible muscle-invasive or metastatic urothelial carcinoma.

Gemcitabine with cisplatin

A common 21-day urothelial regimen uses gemcitabine 1,000 mg/m² IV on days 1 and 8 plus cisplatin 70 mg/m² IV on day 1, usually for 4 neoadjuvant cycles or protocolled advanced-disease treatment.

Assess renal function, hearing, neuropathy, marrow, hydration and magnesium; obtain histology, treat infection and modify or choose an alternative if cisplatin fitness criteria are not met.

Enhances definitive radiotherapy after maximal TURBT in selected muscle-invasive bladder cancer.

Radiosensitising mitomycin with fluorouracil

A common bladder-preservation schedule uses mitomycin 12 mg/m² IV on day 1 plus fluorouracil 500 mg/m²/day by continuous IV infusion during radiotherapy fractions 1–5 and 16–20.

Confirm DPD status before fluorouracil, monitor marrow, renal function, mucositis, diarrhoea and bladder toxicity, and coordinate exact radiation dates through the protocol.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Clot retention and haemorrhage

Heavy bleeding causes painful obstruction, anaemia and transfusion or endoscopic haemostasis need. In Bladder and upper-tract urothelial cancer, this distinction materially changes complication assessment.

Hydronephrosis and renal failure

Tumour at the ureteric orifice, ureter or pelvis obstructs drainage and may require stent or nephrostomy.

Recurrence and progression

Non-muscle-invasive cancer frequently recurs, while high-grade T1 and carcinoma in situ can progress to muscle-invasive and metastatic disease.

Treatment-related urinary dysfunction

Cystectomy, diversion and pelvic radiotherapy can cause infection, renal deterioration, bowel, sexual and continence effects. In Bladder and upper-tract urothelial cancer, this distinction materially changes complication assessment.

Systemic-treatment toxicity

Cisplatin can cause renal, hearing and neurological injury, while immunotherapy and antibody–drug conjugates have distinct serious toxicities.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

After NMIBC treatment, perform risk-based cystoscopy with urine cytology where indicated and investigate symptoms between scheduled examinations.
During BCG, review urinary symptoms, fever, traumatic catheterisation and infection before each instillation; escalate persistent systemic illness urgently.
After cystectomy or urinary diversion, monitor renal function, electrolytes, infection, stones, stoma, continence, sexual function and vitamin B12 where bowel segment dictates.
After bladder-preserving chemoradiotherapy, maintain lifelong cystoscopic and imaging surveillance with rapid access to salvage surgery for invasive recurrence.
During platinum therapy, check counts, renal function, magnesium, hearing, neuropathy, infection and hydration before each dose.
For upper-tract conservative treatment, combine repeated ureteroscopy, cytology and imaging because apparent local clearance does not remove field risk.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

One episode is enough

Visible haematuria warrants evaluation even if transient, painless, culture-positive or occurring during anticoagulation.

Muscle in the specimen matters

Without detrusor muscle, a high-grade tumour may be falsely labelled superficial and offered inadequate intravesical treatment.

BCG fever can be serious

Persistent fever and systemic symptoms after instillation may represent disseminated infection rather than ordinary cystitis.

Preservation needs salvage access

Trimodality therapy is not simply radiotherapy; it requires maximal TURBT, radiosensitisation, cystoscopic assessment and timely salvage cystectomy.

The urothelium is a field

Bladder and upper-tract recurrences can occur after treatment at another site, demanding anatomy-wide surveillance.

11Common pitfallsFrequent interpretation and management errors.

01
Dismissing visible haematuria because the patient takes an anticoagulant.
02
Accepting high-grade T1 staging when detrusor muscle is absent.
03
Giving immediate mitomycin when perforation is possible.
04
Instilling BCG during infection, traumatic catheterisation or visible haematuria.
05
Offering bladder preservation without a salvage-cystectomy pathway.
06
Assuming a small upper-tract biopsy cannot have undergraded invasive disease.